Multi-site study further demonstrate efficacy and quality of life benefits for prostate cancer patients treated with Accuray's Cyberknife® System

Accuray Incorporated (Nasdaq: ARAY), has announced the publication of two papers stemming from a large multi-center study of CyberKnife® stereotactic body radiotherapy (SBRT) led by investigators at the University of California, Los Angeles(UCLA)...